An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells.

Stem Cell Reviews and Reports
Arnab RayRajkumar P Thummer

Abstract

Human induced Pluripotent Stem Cells (iPSCs) have enormous potential in understanding developmental biology, disease modeling, drug discovery, and regenerative medicine. The initial human iPSC studies used fibroblasts as a starting cell source to reprogram them; however, it has been identified to be a less appealing somatic cell source by numerous studies due to various reasons. One of the important criteria to achieve efficient reprogramming is determining an appropriate starting somatic cell type to induce pluripotency since the cellular source has a major influence on the reprogramming efficiency, kinetics, and quality of iPSCs. Therefore, numerous groups have explored various somatic cell sources to identify the promising sources for reprogramming into iPSCs with different reprogramming factor combinations. This review provides an overview of promising easily accessible somatic cell sources isolated in non-invasive or minimally invasive manner such as keratinocytes, urine cells, and peripheral blood mononuclear cells used for the generation of human iPSCs derived from healthy and diseased subjects. Notably, iPSCs generated from one of these cell types derived from the patient will offer ethical and clinical advantages. In a...Continue Reading

References

Sep 22, 1972·Nature·G R Sutherland, A D Bain
Dec 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·G R Martin
Nov 6, 1998·Science·J A ThomsonJ M Jones
Jan 31, 2006·Journal of Cell Science·Laura Alonso, Elaine Fuchs
Feb 23, 2007·Nature·Elaine Fuchs
Mar 21, 2007·Bone Marrow Transplantation·A F CashenS M Devine
Nov 22, 2007·Science·Junying YuJames A Thomson
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·W E LowryK Plath
May 30, 2008·Nature·Tarjei S MikkelsenAlexander Meissner
Sep 13, 2008·Cell Stem Cell·Nimet MaheraliKonrad Hochedlinger
Oct 22, 2008·Nature Biotechnology·Trond AasenJuan Carlos Izpisúa Belmonte
Mar 21, 2009·Blood·Yuin-Han LohGeorge Q Daley
Aug 12, 2009·Nature·Teruhisa KawamuraJuan Carlos Izpisúa Belmonte
Aug 12, 2009·Nature·Han LiManuel Serrano
Oct 3, 2009·Cell Stem Cell·Alessandra GiorgettiJuan Carlos Izpisua Belmonte
May 26, 2010·Stem Cells and Development·Atsushi KunisatoKenji Nagao
Jul 14, 2010·Cell Stem Cell·Yuin-Han LohGeorge Q Daley
Jul 14, 2010·Cell Stem Cell·Judith StaerkRudolf Jaenisch
Oct 20, 2010·Proceedings of the National Academy of Sciences of the United States of America·Thomas SerwoldIrving L Weissman
Jun 4, 2011·Journal of the American Society of Nephrology : JASN·Ting ZhouMiguel A Esteban

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.